Participation of renal and circulating endothelin in salt-sensitive essential hypertension

被引:13
作者
Elijovich, F [1 ]
Laffer, CL [1 ]
机构
[1] Michigan State Univ, Coll Human Med, Dept Med, Med Educ & Res Ctr Grand Rapids, 1000 Monroe Ave NW, Grand Rapids, MI 49503 USA
关键词
endothelin; salt sensitivity; salt; blood pressure;
D O I
10.1038/sj.jhh.1001419
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Salt sensitivity of blood pressure is a cardiovascular risk factor, independent of and in addition to hypertension. In essential hypertension, a conglomerate of clinical and biochemical characteristics defines a salt-sensitive phenotype. Despite extensive research on multiple natriuretic and antinatriuretic systems, there is no definitive answer yet about the major causes of salt-sensitivity, probably reflecting the complexity of salt-balance regulation. The endothelins, ubiquitous peptides first described as potent vasoconstrictors, also have vasodilator, natriuretic and antinatriuretic actions, depending on their site of generation and binding to different receptors. We review the available data on endothelin in salt-sensitive essential hypertension and conclude that abnormalities of renal endothelin may play a primary role. More importantly, the salt-sensitive patient may have blood pressure-dependency on endothelin in all states of salt balance, thus predicting that endothelin receptor blockers will have a major therapeutic role in salt-sensitive essential hypertension.
引用
收藏
页码:459 / 467
页数:9
相关论文
共 103 条
[51]   EFFECT OF CHRONIC TREATMENT OF ADULT SPONTANEOUSLY HYPERTENSIVE RATS WITH AN ENDOTHELIN RECEPTOR ANTAGONIST [J].
LI, JS ;
SCHIFFRIN, EL .
HYPERTENSION, 1995, 25 (04) :495-500
[52]  
Luft FC, 1998, WIEN KLIN WOCHENSCHR, V110, P459
[53]  
Malatino LS, 2000, J NEPHROL, V13, P178
[54]   Adducin in essential hypertension [J].
Manunta, P ;
Barlassina, C ;
Bianchi, G .
FEBS LETTERS, 1998, 430 (1-2) :41-44
[55]   Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension [J].
Matsuoka, H ;
Itoh, S ;
Kimoto, M ;
Kohno, K ;
Tamai, O ;
Wada, Y ;
Yasukawa, H ;
Iwami, G ;
Okuda, S ;
Imaizumi, T .
HYPERTENSION, 1997, 29 (01) :242-247
[56]   Angiotensin II increases tissue endothelin and induces vascular hypertrophy - Reversal by ETA-receptor antagonist [J].
Moreau, P ;
dUscio, LV ;
Shaw, S ;
Takase, H ;
Barton, M ;
Luscher, TF .
CIRCULATION, 1997, 96 (05) :1593-1597
[57]   Sodium sensitivity and cardiovascular events in patients with essential hypertension [J].
Morimoto, A ;
Uzu, T ;
Fujii, T ;
Nishimura, M ;
Kuroda, S ;
Nakamura, S ;
Inenaga, T ;
Kimura, G .
LANCET, 1997, 350 (9093) :1734-1737
[58]   Early abnormalities in left ventricular diastolic function of sodium-sensitive hypertensive patients [J].
Musiari, L ;
Ceriati, R ;
Taliani, U ;
Montesi, MC ;
Novarini, A .
JOURNAL OF HUMAN HYPERTENSION, 1999, 13 (10) :711-716
[59]   Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice [J].
Ohuchi, T ;
Kuwaki, T ;
Ling, GY ;
Dewit, D ;
Ju, KH ;
Onodera, M ;
Cao, WH ;
Yanagisawa, M ;
Kumada, M .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1999, 276 (04) :R1071-R1077
[60]   ETA receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats [J].
Park, JB ;
Schiffrin, EL .
HYPERTENSION, 2001, 37 (06) :1444-1449